• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day

Posted on: Wednesday, 4 March 2009, 07:30 CST

ALISO VIEJO, Calif., March 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has rescheduled the release of its financial results for the fourth quarter and year-ended December 31, 2008 to Wednesday, March 11th in order to complete its year end audit and to more closely coincide with the filing of its Form 10-K for the year ended December 31, 2008.

Date: Wednesday, March 11, 2009 Start Time: 5:00 pm EDT Call-in Number: 1-800-762-8779 (International) 480-248-5081 Conference ID Number: 3992520 Webcast: www.clarientinc.com/investor Web Replay: For those unable to participate during the live broadcast, the webcast replay will be archived at www.clarientinc.com/investor shortly after the call and will be available for one year. Speakers: Ron Andrews, Vice Chairman and CEO; Dr. Mike Pellini, President and COO; Ray Land, CFO Format: Discussion of fourth quarter and year-end 2008 financial results followed by Q&A

About Clarient

Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

About Safeguard Scientifics

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE:SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com

CONTACT: Allen & Caron Inc. Matt Clawson 949.474.4300 matt@allencaron.com

SOURCE Clarient, Inc.

Source: PR Newswire

More News in this Category